ASP Isotopes has seen its share price fall sharply over the past year, even as the business has signed high profile nuclear fuel deals and pushed ahead with new projects. The key issue now is whether the current market value lines up with the revenue the company is actually generating.
The stock's next move may depend on whether ASP Isotopes' current share price can be explained by the revenue it generates right now.
For context on ASP Isotopes and the broader nuclear fuel theme, it helps to compare its recent slide against other nuclear energy infrastructure ideas using the 16 nuclear energy infrastructure stocks.
P/S suits ASP Isotopes because investors are mainly paying for its sales potential rather than current profits. On this yardstick, the stock trades on a P/S of 7.7x, compared with a chemicals industry average of 1.2x and a peer group average of about 0.5x. That is a large premium for each dollar of revenue in a sector where many businesses change hands on much lower sales multiples.
The fair multiple from Simply Wall St’s model, which blends ASP Isotopes' growth profile, margins, size and risk, sits below the current P/S. As a result, the shares screen as overvalued on this framework. Despite the multi year HALEU deal and new facility plans grabbing attention, the present P/S still prices ASP Isotopes well above both its peers and the level the model suggests for its fundamentals. Explore the numbers behind ASP Isotopes's P/S valuation.
Simply Wall St Narratives aim to close the gap between ASP Isotopes' current P/S premium and the question of what kind of future would need to unfold for that valuation to look high or low. Each scenario sets out the specific assumptions on things like growth, profitability and future earnings that sit behind an estimated fair value, so you can later compare those expectations with the numbers ASP Isotopes' management actually delivers.
One of the top narratives on ASP Isotopes: 90% undervalued
This Narrative is the bullish analyst Narrative on Simply Wall St, built on the most optimistic analyst price target and forecasts, not one person's view.
"Expansion of ASP Isotopes’ vertically integrated nuclear medicine pipeline, from enriched isotopes through PET Labs and into the Alpa Theranostics VHH programs, could shift the mix toward higher value radiopharmaceutical revenue..."
Discover why this Narrative puts ASP Isotopes at 90% undervalued.
Before you lean too heavily on ASP Isotopes' sales multiple and growth story, it is worth seeing who has recently been selling shares, how much changed hands and what that might signal for you. See the recent insider selling flagged for ASP Isotopes.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com